PFIZER

Strong Fundamentals, but Valuation Watch 👀💊

rallied 11% post Q4 FY25 results; now trading around 4,886. 📊 Net Profit: ₹330.9 Cr (+85% YoY, incl. ₹172 Cr from Thane sale) 📈 EBITDA Margin: 38.4% | Dividend: ₹165/share (incl. special payouts) ⚠️ With a COVID surge in India and strong fundamentals, Pfizer remains a watchlist stock—though ~45% above intrinsic value.